Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...

Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in ...

Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung ...

The following is a summary of “Outcomes of De Novo Oligometastatic Breast Cancer Treated With Surgery of Primary and ...

The objective response rate was 78.6% in the overall cohort, 76.9% in patients with a PD-L1 combined positive score (CPS) below 1, 68.8% in patients with a PD-L1 CPS of 1-9, and 100% in patients with ...

The FDA approved inavolisib for triplet combination use for treatment of PIK3CA-mutated locally advanced or metastatic ...

Mark A. Lewis, MD, discussed the promise of the ESOPEC and TRANSMET trials and the need for their further investigation.

Combination treatment with retifanlimab, bevacizumab, and hypofractionated radiotherapy — with or without epacadostat — warrants further investigation, according to researchers.

Now, China-based CARsgen has shared pivotal results from the latter portion of a phase 1/2 study evaluating the therapy for ...

Veliparib plus temozolomide did not significantly extend overall survival in patients with newly diagnosed, ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) and keeping the price ...